Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07377435 · ClinicalTrials.gov registry record · Phase 1
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
A Phase 1 study, sponsored by David Avigan.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT07377435 is a Phase 1 study that is actively recruiting participants, run by David Avigan. The registered enrollment target is 25 participants.
The verdict
NCT07377435, a Phase 1 study, is actively recruiting participants, sponsored by David Avigan.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory multiple myeloma. The names of the study drugs involved in this study are: * DC/MM fusion vaccine (a type of personalized cancer vaccine) * Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone)
Interventions
- DRUG GM-CSF
- BIOLOGICAL DC/MM Fusion Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2032-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07377435
The ClinicalTrials.gov registry entry for NCT07377435 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Avigan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GM-CSF is the first listed.
NCT07377435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07377435 about?
NCT07377435 is a clinical study titled "DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM". This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory multiple myeloma. The names of the study drugs involved in this study are: ...
What is the current status of trial NCT07377435?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2026-01-30. Estimated completion is 2032-03-01.
What interventions are being tested in trial NCT07377435?
The interventions under investigation include: GM-CSF (DRUG), DC/MM Fusion Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07377435?
This trial is sponsored by David Avigan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.